After Roe v. Wade was overturned, a law still on the books from 1849 left the legality of abortions in dispute in the state. This week, Planned Parenthood resumes services.

At a recent medical gathering, researchers presented their latest hypotheses about what causes – and what could treat – the lingering disease.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

New companies are working to commercialize in vitro gametogenesis, or IVG, a technology that could make human eggs and sperm in the lab from any cell in the body.

Taken after sex, the antibiotic doxycycline can ward off some sexually transmitted illnesses. Doctors are already prescribing it and the CDC is expected to share guidance soon for how best to use it.

Calliope Holingue researches how the microbiome and mind affect each other. She's part of a growing field, exploring how that connection could ultimately improve treatments for mental conditions.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

The Food and Drug Administration approved the first gene therapy for Duchenne muscular dystrophy, but limited access to those ages four and five.

Diseases like Alzheimer's and Parkinson's spread through the brain like a forest fire. A new study suggests how the fire starts.

Scientists have shown that deep brain stimulation during sleep can help people retain new information. The approach could help people with memory problems related to disorders like Alzheimer's.

At least 58,000 childern younger than 5 years old are hospitalized each year with RSV infections. A Pfizer vaccine given to pregnant people could help protect their infants from severe RSV illness.

Children who need growth hormone to achieve their full stature are having trouble getting the medicine. A shortage has stretched months longer than expected and could last the rest of the year.

A panel of experts voted 8-6 in favor of Food and Drug Administration approval of the first gene therapy for Duchenne muscular dystrophy, a fatal genetic disease.

The FDA is considering greenlighting the experimental treatment under its accelerated approvals program. Some critics point out the therapy isn't yet proven to work and may be costly.

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.